NASDAQ:CAPS Capstone Therapeutics (CAPS) Stock Price, News & Analysis $1.23 -0.19 (-13.38%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About Capstone Therapeutics Stock (NASDAQ:CAPS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capstone Therapeutics alerts:Sign Up Key Stats Today's Range$1.23▼$1.3850-Day Range$1.01▼$1.8852-Week Range$0.96▼$16.18Volume577,088 shsAverage Volume5.49 million shsMarket Capitalization$6.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona. Read More Receive CAPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPS Stock News HeadlinesMichael ParkerJune 18, 2025 | latimes.comCapstone Holding Corp., Secures $1 Million Pangaea Stone Order in Expanding TerritoryJune 17, 2025 | finanznachrichten.deTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 27 at 2:00 AM | Porter & Company (Ad)Pinecrest, Florida Resident David Buitrago Completes Intensive Capstone Research ProjectJune 16, 2025 | msn.comA capstone projectJune 14, 2025 | yahoo.comCSM Honors 32 Leaders in 2025 Academy CeremonyJune 14, 2025 | msn.comCapstone Holding Corp. (J7W.F)June 12, 2025 | finance.yahoo.comStudents At NHTI, Concord’s Community College, Solve DNA Extraction ConundrumJune 10, 2025 | msn.comSee More Headlines CAPS Stock Analysis - Frequently Asked Questions How have CAPS shares performed this year? Capstone Therapeutics' stock was trading at $2.40 at the start of the year. Since then, CAPS shares have decreased by 48.8% and is now trading at $1.23. How were Capstone Therapeutics' earnings last quarter? Capstone Therapeutics Corp. (NASDAQ:CAPS) posted its quarterly earnings results on Friday, August, 15th. The company reported ($0.13) EPS for the quarter. The business had revenue of $12.85 million for the quarter. When did Capstone Therapeutics IPO? Capstone Therapeutics (CAPS) raised $5 million in an IPO on Thursday, March 6th 2025. The company issued 1,250,000 shares at a price of $4.00 per share. When does the company's lock-up period expire? Capstone Therapeutics's lock-up period expires on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. How do I buy shares of Capstone Therapeutics? Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/15/2025Today8/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPS CIK887151 WebN/A Phone(708) 371-0660Fax602-286-5300Employees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.22 Current Ratio0.97 Quick Ratio0.41 Sales & Book Value Annual Sales$44.88 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book0.26Miscellaneous Outstanding Shares5,580,000Free Float3,192,000Market Cap$6.86 million OptionableN/A Beta-0.80 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CAPS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.